Navigation Links
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Repros Therapeutics, Inc.
Date:10/23/2013

NEW YORK, Oct. 23, 2013 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Repros Therapeutics, Inc. ("Repros" or the "Company") (NasdaqCM: RPRX).  Such investors are advised to contact Peretz Bronstein or his Investor Relations coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484.

The investigation concerns whether Repros and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Shares of Repros fell $7.17 or 30.27% during intraday trading to trade at $16.52 after the company delayed its filing for marketing approval of its testosterone replacement Androxal for several months. Repros said it now expects to file for approval in the fourth quarter of 2014, after it completes two studies of the drug. It had planned to make its filing in the middle of 2014. The company said the Food and Drug Administration wants a year of study data on the effects of the highest dose of Androxal. The agency also told Repros to request a meeting to discuss the studies the company has conducted. On September 18, 2013, the company disclosed in a press release that it is "completely satisfied that all data entered into the data base for study ZA-301 will pass any scrutiny the FDA chooses to apply."

If you are aware of any facts relating to this investigation, or purchased shares of Repros, you can assist this investigation by contacting Peretz Bronstein or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com.  Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
info@bgandg.com


'/>"/>
SOURCE Bronstein, Gewirtz & Grossman, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AMAG Pharmaceuticals, Inc. -- AMAG
2. China Nepstar Chain Drugstore Schedules Annual General Meeting of Shareholders for October 25, 2013
3. SHAREHOLDER ALERT: Law Office of Brodsky & Smith, LLC Announces Investigation of Astex Pharmaceuticals, Inc.
4. Buyout Alert -- Astex Pharmaceuticals -- Law Firm Seeks Higher Price For Shareholders
5. Hi Tech Shareholder Alert - Buyout Of Hi Tech - Law Firm Seeks Higher Price For Shareholders
6. Shareholder Alert: Pomerantz Law Firm has filed a Class Action Against Biolase, Inc. and Certain Officers - BIOL
7. Acquisition of Onyx Pharmaceuticals, Inc. by Amgen Inc. May Not Be in the Best Interests of Onyx Pharmaceuticals, Inc. Shareholders
8. Concord Medical Announces Acquisition of Its Shares by CEO and COO from Other Shareholders
9. OPTIMER PHARMACEUTICALS SHAREHOLDER ALERT: Levi & Korsinsky Investigates Possible Breaches of Fiduciary Duty by Board of Optimer Pharmaceuticals, Inc. in Connection with Sale of Company to Cubist Pharmaceuticals, Inc.
10. FDA Approvals, Dividends, New Technologies, and Solid Margins Increase Shareholder Value - Research Report on Abbott, Baxter, CareFusion, Haemonetics, and CR Bard
11. Teamsters Protest McKessons Worker Abuse And Executive Pay At Shareholder Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)...   , Study met ... and superiority in , Excellent plus ... of the ascending colon   , ... B.V. today announced new positive data from the phase III MORA ... standard 2 litre PEG with ascorbate. The study met both primary ...
(Date:5/24/2016)... Celsion Corporation (NASDAQ: CLSN ... an update on its ongoing OVATION study, a ... the Company,s DNA-based immunotherapy, with the standard of ... advanced ovarian cancer who will undergo neoadjuvant chemotherapy ... IL-12 DNA plasmid vector formulated as a nanoparticle ...
(Date:5/24/2016)... KONG , May 24, 2016 /PRNewswire/ ... COMBO ™ , la première ... des cathéters destinés à l,intervention portant sur ... (FAV)   OrbusNeich, entreprise mondiale ... permettant de changer la vie, a élargi ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... (PRWEB) May 24, 2016 -- Grow Healthy ... Advisory Board. Joining the Grow Healthy Advisory Board team are ... embody the mission of our organization and bring talent, expertise and ... as we continue to expand our footprint as the leader in ...
(Date:5/24/2016)... , ... May 24, 2016 , ... ... choose the perfect data logger for each job, ensuring the best suited solution ... calibrations of MadgeTech data loggers at their lab in Istanbul. , Metroloji Okulu ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... and clinical practice of radiosurgery, is recognizing five medical residents and students for ... stereotactic body radiotherapy (SBRT). The awards will be presented at the 2016 SRS/SBRT ...
(Date:5/24/2016)... ... May 24, 2016 , ... Bio-Logic Aqua® Research ... forty years and a trainer for Ageless Grace ( http://www.agelessgrace.com ) to discuss ... on May 16, 2016. , Formerly a Northwestern University Literature Professor, Kinst gravitated ...
(Date:5/24/2016)... , ... May 24, 2016 , ... In light of ... aware of the potential of contaminated well water throughout the Houston area. , Heavy ... with well water that’s exposed to contaminants. Residents may not even be aware of ...
Breaking Medicine News(10 mins):